Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis

Journal of Immunology

Volumn 170, Issue 9, 2003, Pages 4793-4801

  Wunder, Andreas ^a   Müller Ladner, Ulf ^b   Stelzer, Ernst H K ^c   Funk, Jürgen ^d   Neumann, Elena ^b   Stehle, Gerd ^d   Pap, Thomas ^e   Sinn, Hannsjörg ^a   Gay, Steffen ^e   Fiehn, Christoph ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DRUG CARRIER; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; DRUG UPTAKE; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYNOVIUM; TUMOR;

EID: 0242416983     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.9.4793     Document Type: Article

References (39)

1. Gay, S., R. E. Gay, and W. J. Koopman. 1993. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann. Rheum. Dis. 52(Suppl. 1): S39.
2. Firestein, G. S. 1996. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors? Arthritis Rheum. 39:1781.
3. Pap, T., U. Müller-Ladner, R. E. Gay, and S. Gay. 2000. Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2:361.
4. Müller-Ladner, U., R. E. Gay, and S. Gay. 1998. Molecular biology of cartilage and bone destruction. Curr. Opin. Rheumatol. 10:212.
5. Keyszer, G. M., A. H. Heer, J. Kriegsmann, T. Geiler, A. Trabandt, M. Keysser, R. E. Gay, and S. Gay. 1995. Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis Rheum. 38:976.
6. Furst, D. E. 1997. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br. J. Rheumatol. 36:1196.
7. O'Dell, J. R. 1997. Methotrexate use in rheumatoid arthritis. Rheum. Dis. Clin. N. Am. 23:779.
8. Bertino, J. R. 1993. Ode to methotrexate. J. Clin. Oncol. 11:5.
9. Kaye, S. B. 1998. New antimetabolites in cancer chemotherapy and their clinical impact. Br. J. Cancer 78(Suppl. 3):1.
10. Herman, R. A., P. Veng Pedersen, J. Hoffman, R. Koehnke, and D. E. Furst. 1989. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J. Pharm. Sci. 78:165.
11. Furst, D. E. 1995. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br. J. Rheumatol. 34(Suppl. 2):20.
12. Bannwarth, B., F. Pehourcq, T. Schaeverbeke, and J. Dehais. 1996. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet. 30:194.
13. Gupta, P. K., J. B. Cannon, and A. K. Tibrewal. 1996. Targeted drug delivery. In Principles of Antineoplastic Drug Development and Pharmacology. R. L. Schilsky, G. A. Milano, and M. J. Ratain. eds. Marcel Dekker, New York, p. 587.
14. Singh, M., A. J. Ferdous, M. Branham, and G. V. Betageri. 1996. Trends in drug targeting for cancer treatment. Drug Deliv. 3:289.
15. Mider, G. B., H. Tesluk, and J. J. Morton. 1948. Effects of Walker carcinoma 256 on food intake, body weight and nitrogen metabolism of growing rats. Acta Unio Int. Contra Cancrum 6:409.
16. Babson, A. L., and T. Winnick. 1954. Protein transfer in tumor-bearing rats. Cancer Res. 14:606.
17. Andersson, C., B. M. Iresjo, and K. Lundholm. 1991. Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice. J. Surg. Res. 50:156.
18. Wunder, A., G. Stehle, H. Sinn, H. H. Schrenk, D. Hoff-Biederbeck, F. Bader, E. A. Friedrich, P. Peschke, W. Maier-Borst, and D. L. Heene. 1997. Enhanced albumin uptake by rat tumors. Int. J. Oncol. 11:497.
19. Stehle, G., H. Sinn, A. Wunder, H. H. Schrenk, J. C. M. Stewart, G. Hartung, W. Maier-Borst, and D. L. Heene. 1997. Plasma protein (albumin) catabolism by the tumor itself: implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol. 26:77.
20. Jain, R. K. 1988. Determinants of tumor blood flow: a review. Cancer Res. 48:2641.
21. Stehle, G., H. Sinn, A. Wunder, H. H. Schrenk, S. Schütt, D. L. Heene, and W. Maier-Borst. 1997. The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anticancer Drugs 8:677.
22. Stehle, G., A. Wunder, H. Sinn, H. H. Schrenk, S. Schütt, E. Frei, G. Hartung, W. Maier-Borst, and D. L. Heene. 1997. Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats. Anticancer Drugs 8:835.
23. Wunder, A., G. Stehle, H. H. Schrenk, G. Hartung, E. Frei, D. L. Heene, W. Maier-Borst, and H. Sinn. 1998. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinosarcoma. Int. J. Cancer 76:884.
24. Stehle, G., A. Wunder, H. H. Schrenk, G. Hartung, D. L. Heene, and H. Sinn. 1999. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 Hi prostate cancer bearing rats. Anticancer Drugs 10:405.
25. Burger, A. M., G. Hartung, G. Stehle, H. Sinn, and H. H. Fiebig. 2001. Preclinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int. J. Cancer 92:718.
26. Hartung, G., G. Stehle, H. Sinn, A. Wunder, H. H. Schrenk, S. Heeger, M. Kränzle, H. H. Fiebig, E. Frei, L. Edler, et al. 1999. Phase-1 trial of methotrexate-albumin (MTX-HSA) in a weekly intravenous bolus regimen in cancer patients. Clin. Cancer Res. 5:753.
27. Levick, J. R. 1981. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 24:1550.
28. Wilkinson, P., R. Jeremy, F. P. Brooks, and J. L. Hollander. 1965. The mechanism of hypoalbuminemia in rheumatoid arthritis. Ann. Intern. Med. 63:109.
29. Ballantyne, F. C., A. Fleck, and W. C. Dick. 1971. Albumin metabolism in rheumatoid arthritis. Ann. Rheum. Dis. 30:265.
30. Niwa, Y., A. Iio, G. Niwa, T. Sakane, T. Tsunematsu, and T. Kanoh. 1990. Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer. J. Clin. Lab. Immunol. 31:11.
31. Rinaldi, N., M. Schwarz Eywill, D. Weis, P. Leppelmann Jansen, M. Lukoschek, U. Keilholz, and T. F. Barth. 1997. Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann. Rheum. Dis. 56:45.
32. Wooley, P. H. 1988. Collagen-induced arthritis in the mouse. Methods Enzymol. 162:361.
33. Judex, M., E. Neumann, M. Fleck, T. Pap, J. Mountz, R. E. Gay, J. Scholmerich, K, Nishioka, S. Gay, and U. Müller-Ladner. 2001. "Inverse wrap": an improved implantation technique for virus-transduced synovial fibroblasts in the SCID mouse model for rheumatoid arthritis (RA). Mod. Rheumatol. 11:145.
34. Wooley, P. H. 1991. Animal models of rheumatoid arthritis. Curr. Opin. Rheumatol. 3:407.
35. Myers, L. K., E. F. Rosloniec, M. A. Cremer, and A. H. Kang, 1997. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61:1861.
36. Joe, B., and R. L. Wilder. 1999. Animal models of rheumatoid arthritis. Mol. Med. Today 5:367.
37. Müller-Ladner, U., J. Kriegsmann, B. N. Franklin, S. Matsumoto, T. Geiler, R. E. Gay, and S. Gay. 1996. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol. 149:1607.
38. Müller-Ladner, U., C. H. Evans, B. N. Franklin, C. R. Roberts, R. E. Gay, P. D. Robbins, and S. Gay. 1999. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum. 42:490.
39. Stehle, G., A. Wunder, H. H. Schrenk, G. Hartung, D. L. Heene, and H. Sinn. 1999. Albumin-based drug carriers: comparison between serum albumins of different species on pharmakokinetics and tumor uptake of the conjugate. Anticancer Drugs 10:785.